Details of the Drug

General Information of Drug (ID: DMT2IWF)

Drug Name

APH-1105

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03806478) Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD). U.S.National Institutes of Health.
2	Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021 May 25;7(1):e12179.